6:01 PM
 | 
Dec 14, 2011
 |  BC Extra  |  Company News

BMS, Simcere in deal for CETP inhibitor

Bristol-Myers Squibb Co. (NYSE:BMY) granted Simcere Pharmaceutical Group (NYSE:SCR) exclusive rights in China to develop and commercialize preclinical cardiovascular compound BMS-795311....

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >